Biospecimen and Biomarker Specialist Adds Next-Generation Capability of OLINK® EXPLORE HT
HUNTSVILLE, Ala., Oct. 05, 2023 /PRNewswire/ — Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, today announced it has expanded its high-throughput proteomics services with the addition of Olink® Explore HT. A next-generation proteomics solution, the new Olink Explore HT platform achieves greater precision and speed—enhancing Discovery’s position as a comprehensive provider of proteomics and multi-omic services.
- Deepening biological insights for a nuanced understanding of disease mechanisms.
- Enhancing biomarker discovery for pre-clinical development and clinical trials.
- Powering high-throughput proteomic analysis for population-scale health studies.
To learn more about Discovery’s proteomic services capabilities, please visit https://www.dls.com/biomarker-services/proteomics.
About Discovery Life Sciences
Through AllCells, our cell and gene therapy brand, we maintain a substantial recallable donor pool, supplying Research Use Only (RUO) and clinical-grade fresh and cryopreserved human cellular materials to support cell and gene therapy programs at any phase of development and scale.